You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 7, 2024

~ Buy the EXFORGE HCT (amlodipine besylate; hydrochlorothiazide; valsartan) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR EXFORGE HCT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for EXFORGE HCT

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00523744 ↗ Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension Completed Novartis Phase 3 2007-07-01 This study will evaluate the efficacy and safety of valsartan and amlodipine in fixed dose combination in adults with moderate, inadequately controlled hypertension. There was an optional study extension for eligible patients who wanted to participate that contains the triple therapy (ie, hydrochlorothiazide+ amlodipine/valsartan).
NCT01070043 ↗ To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone Completed Novartis Phase 4 2009-06-01 The purpose of the study was to assess efficacy and safety of fixed dose combination of 5 mg amlodipine/80 mg valsartan compared to 160 mg valsartan monotherapy in lowering blood pressure in Taiwanese patients.
NCT01167153 ↗ Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients Completed Novartis Phase 4 2010-05-01 The purpose of this study was to compare the efficacy and safety of Valsartan/Amlodipine (EXforge®) with nifedipine, as well as vascular function index.
NCT01494727 ↗ Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg Completed CJ HealthCare Corporation Phase 1 2012-02-01 The objectives of this study are: - To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers - To compare the pharmacokinetic profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers
NCT01494727 ↗ Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg Completed HK inno.N Corporation Phase 1 2012-02-01 The objectives of this study are: - To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers - To compare the pharmacokinetic profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers
NCT01735890 ↗ Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet Completed CJ HealthCare Corporation Phase 1 2012-09-01 The objectives of this study are: - To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers - To compare the pharmacokinetic profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers
NCT01735890 ↗ Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet Completed HK inno.N Corporation Phase 1 2012-09-01 The objectives of this study are: - To compare the safety profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers - To compare the pharmacokinetic profile of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg after a single oral administration in healthy male volunteers
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for EXFORGE HCT

Condition Name

Condition Name for EXFORGE HCT
Intervention Trials
Healthy 6
Hypertension 4
Hyperlipidemias 1
Essential Hypertension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for EXFORGE HCT
Intervention Trials
Hypertension 4
Essential Hypertension 1
Hyperlipidemias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for EXFORGE HCT

Trials by Country

Trials by Country for EXFORGE HCT
Location Trials
Korea, Republic of 7
Germany 1
China 1
Egypt 1
Taiwan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for EXFORGE HCT

Clinical Trial Phase

Clinical Trial Phase for EXFORGE HCT
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 1 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for EXFORGE HCT
Clinical Trial Phase Trials
Completed 13
Not yet recruiting 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for EXFORGE HCT

Sponsor Name

Sponsor Name for EXFORGE HCT
Sponsor Trials
CJ HealthCare Corporation 6
HK inno.N Corporation 6
Novartis 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for EXFORGE HCT
Sponsor Trials
Industry 19
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.